Cargando…
A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is involved in many cancers and EGFR has been heavily pursued as a drug target. Drugs targeting EGFR have shown promising clinical results for several cancer types. However, resistance to EGFR inhibitors often occurs, such as with KRAS mutant cancers, ther...
Autores principales: | Boran, Aislyn D. W., Seco, Joseph, Jayaraman, Vinodh, Jayaraman, Gomathi, Zhao, Shan, Reddy, Sushmitha, Chen, Yibang, Iyengar, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499488/ https://www.ncbi.nlm.nih.gov/pubmed/23166750 http://dx.doi.org/10.1371/journal.pone.0049702 |
Ejemplares similares
-
Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses
por: Tavassoly, Iman, et al.
Publicado: (2019) -
Influence of Macrocyclization on Allosteric, Juxtamembrane-Derived,
Stapled Peptide Inhibitors of the Epidermal Growth Factor Receptor
(EGFR)
por: Sinclair, Julie K.-L., et al.
Publicado: (2014) -
The synaptotagmin juxtamembrane domain is involved in neuroexocytosis
por: Caccin, Paola, et al.
Publicado: (2015) -
Peptides derived from cadherin juxtamembrane region inhibit platelet function
por: Golla, Kalyan, et al.
Publicado: (2018) -
Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence
por: He, Lijuan, et al.
Publicado: (2012)